We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Valneva SE | EU:VLA | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.38 | 3.372 | 3.402 | 0.00 | 01:00:00 |
From May 2022 to May 2024
By Maitane Sardon
Pfizer Inc. and Valneva SE have decided to halt some clinical trials testing its vaccine against Lyme disease following violations of good practices at certain clinical trial sites, Valneva said Friday.
The decision affects a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists Phase 3 clinical study, the French biotech company said.
The study participants, which represent roughly half of the total recruited participants in the trial, are being excluded following violations of good clinical practice at certain clinical trial sites run by a third-party operator, it said.
Valneva said the decision wasn't related to any safety concerns with the vaccine nor was it prompted by a participant-reported adverse event, noting that the trial remains ongoing at other sites not operated by the third party.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
February 17, 2023 02:58 ET (07:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Valneva Chart |
1 Month Valneva Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
